Patient anxiety about prostate cancer independently predicts early initiation of androgen deprivation therapy for biochemical cancer recurrence in older men: A prospective cohort study

Journal of Clinical Oncology

Volumn 27, Issue 10, 2009, Pages 1557-1563

  Dale, William ^a   Hemmerich, Joshua ^a   Bylow, Kathryn ^a   Mohile, Supriya ^a   Mullaney, Mary ^a   Stadler, Walter M ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN;

AGED; ANDROGEN DEPRIVATION THERAPY; ANXIETY; ARTICLE; CANCER RECURRENCE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORIAL ANXIETY SCALE FOR PROSTATE CANCER; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE;

AGED; ANGIOGENESIS INHIBITORS; ANXIETY; COHORT STUDIES; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS; QUALITY OF LIFE;

EID: 63749112245     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.18.5850     Document Type: Article

References (35)

1. Freedland SJ, Humphreys EB, Mangold LA, et al: Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294:433-439, 2005
2. Ryan CJ, Small EJ: High-risk biochemical relapse and the timing of androgen deprivation therapy. J Urol 176:S61-S65, 2006
3. Loblaw DA, Virgo KS, Nam R, et al: Initial hormonal management of androgen-sensitive meta- static, recurrent, or progressive prostate cancer: 2007 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 25:1596-1605, 2007
4. Lubeck DP, Gary DG, Peter RC: The effect of androgen deprivation therapy on health-related quality of life in men with prostate cancer. Urology 58:94-99, 2001
5. van Andel G, Kurth KH: The impact of androgen deprivation therapy on health related quality of life in asymptomatic men with lymph node positive prostate cancer. Eur Urol 44:209-214, 2003
6. Higano CS: Side effects of androgen deprivation therapy: Monitoring and minimizing toxicity. Urology 61:32-38, 2003 (suppl 1)
7. Dacal K, Sereika SM, Greenspan SL: Quality of life in prostate cancer patients taking androgen deprivation therapy. J Am Geriatr Soc 54:85-90, 2006
8. Berruti A, Dogliotti L, Terrone C, et al: Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 167:2361-2367, 2002; discussion 2367
9. Boxer RS, Kenny AM, Dowsett R, et al: The effect of 6 months of androgen deprivation therapy on muscle and fat mass in older men with localized prostate cancer. Aging Male 8:207-212, 2005
10. Smith M: Osteoporosis and other adverse body composition changes during androgen deprivation therapy for prostate cancer. Cancer Metastasis Rev 21:159-166, 2002
11. Bylow K, Dale W, Mustian K, et al: Falls and physical performance deficits in older prostate cancer patients undergoing androgen deprivation therapy. Urology (in press)
12. Tsai HK, D'Amico AV, Sadetsky N, et al: androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 99:1516-1524, 2007
13. Bayoumi AM, Brown AD, Garber AM: Cost- effectiveness of androgen suppression therapies in advanced prostate cancer. J Natl Cancer Inst 92: 1731-1739, 2000
14. Zeliadt SB, Ramsey SD, Penson DF, et al: Why do men choose one treatment over another? A review of patient decision making for localized prostate cancer. Cancer 106:1865-1874, 2006
15. Sanda MG, Dunn RL, Michalski J, et al: Quality of life and satisfaction with outcome among prostate cancer survivors. N Engl J Med 358:12501261, 2008
16. Loblaw DA, Mendelson DS, Talcott JA, et al: American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol 22:29272941, 2004
17. Walsh PC, Deweese TL, Eisenberger MA: A structured debate: Immediate versus deferred an- drogen suppression in prostate cancer-Evidence for deferred treatment. J Urol 166:508-515, 2001; discussion 515-516
18. Shahinian VB, Kuo YF, Freeman JL, et al: Determinants of androgen deprivation therapy use for prostate cancer: Role of the urologist. J Natl Cancer Inst 98:839-845, 2006
19. Dale W, Bilir P, Han M, Meltzer D: The role of anxiety in prostate carcinoma: A structured review of the literature. Cancer 104:467-478, 2005
20. Latini DM, Hart SL, Knight SJ, et al: The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance. J Urol 178:826-832, 2007; discussion 831-832
21. Bubley GJ, Carducci M, Dahut W, et al: Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17:3461-3467, 1999
22. Roth AJ, Rosenfeld B, Kornblith AB, et al: The Memorial Anxiety Scale for prostate cancer: Validation of a new scale to measure anxiety in men with prostate cancer. Cancer 97:2910-2918, 2003
23. Roth AJ, Nelson CJ, Rosenfeld B, et al: Assessing anxiety in men with prostate cancer: Further data on the reliability and validity of the Memorial Anxiety Scale for prostate cancer (MAX-PC). Psy-chosomatics 47:340-347, 2006
24. Dale W, Hemmerich J, Meltzer D: Extending the validity of the Memorial Anxiety Scale for Prostate Cancer (MAX-PC) at the time of prostate biopsy in a racially-mixed population. Psychooncology 16:493-498, 2007
25. Zigmund AS, Snaith RP: The Hospital Anxiety and Depression Scale. Acta Psychiatrica Scandinavia 67:361-370, 1983
26. Bjelland I, Dahl AA, Haug TT, et al: The validity of the Hospital Anxiety and Depression Scale: An updated literature review. J Psychosomatic Res 52:69-77, 2002
27. Buhr K, Dugas MJ: The intolerance of uncertainty scale: Psychometric properties of the English version. Behav Res Therapy 40:931-945, 2002
28. Mohile S, Bylow K, Dale W, et al: A pilot study of the Vulnerable Elders Survey-13 (VES-13) as compared to the Comprehensive Geriatric Assessment (CGA) for identifying disability in older prostate cancer patients receiving androgen ablation. Cancer 109:802-810, 2007
29. Ahmad F, Hemmerich J, Bylow K, Stadler WM, Dale W: Variance in physician attitudes toward andro- gen deprivation therapy initiation for rising PSA for asymptomatic recurrent prostate cancer. http://lungca.asco.org/ASCO/Abstracts+ &+Virtual + Meeting/ Abstracts?&vmview=abst-detail-view&confID= 46& abstractID=20510
30. Pound CR, Partin AW, Eisenberger MA, et al: Natural history of progression after psa elevation following radical prostatectomy. JAMA 281:15911597, 1999
31. D'Amico AV, Moul JW, et al: Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 95:1376-1383, 2003
32. 32.Eisenberger MA, Blumenstein BA, Crawford ED, et al: Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 339:1036-1042, 1998
33. Lu-Yao GL, Albertsen PC, Moore DF, et al: Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 300:173-181, 2008
34. Bylow K, Mohile SG, Stadler WM, Dale W: Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer? Cancer 110:2604-2613, 2007
35. Smith MR: Androgen deprivation therapy for prostate cancer: New concepts and concerns. Curr Opin Endocrinol Diabetes Obes 14:247-254, 2007